Iijima Raisuke, Ndrepepa Gjin, Kujath Vivien, Harada Yukinori, Kufner Sebastian, Schunkert Heribert, Nakamura Masato, Kastrati Adnan
Division of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo, Japan.
Deutsches Herzzentrum München, Technische Universität, Lazarettstrasse 36, 80636, Munich, Germany.
Heart Vessels. 2017 Apr;32(4):376-384. doi: 10.1007/s00380-016-0889-8. Epub 2016 Aug 24.
The frequency and pattern of progression or regression of coronary atherosclerosis in contemporary patients with diabetes remain unknown. This study included 605 patients with coronary artery disease (CAD). Two coronary angiographic examinations at baseline and after 2 years were performed. The analysis focused on non-stented segments with diameter stenosis ≥25 %. Atherosclerosis progression (or regression) was defined as a decrease (or increase) in the mean minimal lumen diameter (MLD) in the 2-year angiogram compared to mean MLD in the baseline angiogram of >0.2 mm. Statins were prescribed in 576 patients (95.2 %). The primary outcome was atherosclerosis progression or regression in the 2-year angiogram. One hundred sixty-nine patients (28 %) had diabetes. Diabetic patients had greater reduction of mean MLD in the 24 angiogram compared to baseline angiogram than nondiabetic patients (0.11 ± 0.18 vs. -0.08 ± 0.15 mm, P < 0.001). Atherosclerosis progression was observed in 37 patients with diabetes and 16 nondiabetic patients (21.9 vs. 3.7 %; P < 0.001). Atherosclerosis regression was observed in two diabetic patients and 78 nondiabetic patients (1.2 vs. 17.9 %; P < 0.001). A progression pattern across all coronary segments was observed in 70 patients (41.4 %) with diabetes and 60 patients (13.8 %) without diabetes (P < 0.001). Diabetic patients with a low-density lipoprotein cholesterol ≥70 mg/dl showed more atherosclerosis progression than diabetic patients with LDL cholesterol <70 mg/dl (delta-MLD: 0.12 ± 0.19 vs. 0.08 ± 0.16 mm; P = 0.04). In conclusion, in contemporary patients with CAD treated with moderate-intensity statin therapy, diabetes is associated with the increased risk of progression and decreased probability of regression of coronary atherosclerosis.
当代糖尿病患者冠状动脉粥样硬化进展或消退的频率和模式尚不清楚。本研究纳入了605例冠心病(CAD)患者。在基线和2年后进行了两次冠状动脉血管造影检查。分析重点为直径狭窄≥25%的未置入支架节段。动脉粥样硬化进展(或消退)定义为2年血管造影中平均最小管腔直径(MLD)相较于基线血管造影中的平均MLD减少(或增加)>0.2 mm。576例患者(95.2%)服用了他汀类药物。主要结局是2年血管造影中的动脉粥样硬化进展或消退。169例患者(28%)患有糖尿病。与非糖尿病患者相比,糖尿病患者2年血管造影中平均MLD较基线血管造影的降低幅度更大(0.11±0.18 vs. -0.08±0.15 mm,P<0.001)。37例糖尿病患者和16例非糖尿病患者出现动脉粥样硬化进展(21.9% vs. 3.7%;P<0.001)。2例糖尿病患者和78例非糖尿病患者出现动脉粥样硬化消退(1.2% vs. 17.9%;P<0.001)。70例(41.4%)糖尿病患者和60例(13.8%)非糖尿病患者观察到所有冠状动脉节段均有进展模式(P<0.001)。低密度脂蛋白胆固醇≥70 mg/dl的糖尿病患者比低密度脂蛋白胆固醇<70 mg/dl的糖尿病患者表现出更多的动脉粥样硬化进展(MLD变化值:0.12±0.19 vs. 0.08±0.16 mm;P=0.04)。总之,在当代接受中等强度他汀类药物治疗的CAD患者中,糖尿病与冠状动脉粥样硬化进展风险增加及消退概率降低相关。